|
1
|
van Gestel YR, Thomassen I, Lemmens VE,
Pruijt JF, van Herk-Sukel MP, Rutten HJ, Creemers GJ and de Hingh
IH: Metachronous peritoneal carcinomatosis after curative treatment
of colorectal cancer. Eur J Surg Oncol. 40:963–969. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Franko J, Shi Q, Goldman CD, Pockaj BA,
Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR and Sargent
DJ: Treatment of colorectal peritoneal carcinomatosis with systemic
chemotherapy: A pooled analysis of north central cancer treatment
group phase III trials N9741 and N9841. J Clin Oncol. 30:263–267.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Razenberg LG, van Gestel YR, Lemmens VE,
de Hingh IH and Creemers GJ: Bevacizumab in addition to palliative
chemotherapy for patients with peritoneal carcinomatosis of
colorectal origin: A nationwide population-based study. Clin
Colorectal Cancer. 15:e41–e46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamada Y, Takahari D, Matsumoto H, Baba H,
Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y,
et al: Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab
versus S-1 and oxaliplatin plus bevacizumab in patients with
metastatic colorectal cancer (SOFT): An open-label,
non-inferiority, randomised phase 3 trial. Lancet Oncol.
14:1278–1286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shirasaka T: Development history and
concept of an oral anticancer agent S-1 (TS-1): Its clinical
usefulness and future vistas. Jpn J Clin Oncol. 39:2–15. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arai W, Hosoya Y, Hyodo M, Yokoyama T,
Hirashima Y, Yasuda Y, Nagai H and Shirasaka T: Alternate-day oral
therapy with TS-1 for advanced gastric cancer. Int J Clin Oncol.
9:143–148. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arai W, Hosoya Y, Haruta H, Kurashina K,
Saito S, Hirashima Y, Yokoyama T, Zuiki T, Sakuma K, Hyodo M, et
al: Comparison of alternate-day versus consecutive-day treatment
with S-1: Assessment of tumor growth inhibition and toxicity
reduction in gastric cancer cell lines in vitro and in vivo. Int J
Clin Oncol. 13:515–520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tatebe S, Tsujitani S, Nakamura S, Shimizu
T, Yamane N, Nishidoi H, Kurisu Y, Kanayama H, Ogawa H and Ikeguchi
M: Feasibility study of alternate-day S-1 as adjuvant chemotherapy
for gastric cancer: A randomized controlled trial. Gastric Cancer.
17:508–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim ST, Hong YS, Lim HY, Lee J, Kim TW,
Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, et al: S-1 plus
oxaliplatin versus capecitabine plus oxaliplatin for the first-line
treatment of patients with metastatic colorectal cancer: Updated
results from a phase 3 trial. BMC Cancer. 14:8832014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hong YS, Park YS, Lim HY, Lee J, Kim TW,
Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, et al: S-1 plus
oxaliplatin versus capecitabine plus oxaliplatin for first-line
treatment of patients with metastatic colorectal cancer: A
randomised, non-inferiority phase 3 trial. Lancet Oncol.
13:1125–1132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shirasaka T, Shimamoto Y and Fukushima M:
Inhibition by oxonic acid of gastrointestinal toxicity of
5-fluorouracil without loss of its antitumor activity in rats.
Cancer Res. 53:4004–4009. 1993.PubMed/NCBI
|
|
12
|
Matsuda C, Uemura M, Nakata K, Shingai T,
Nishimura J, Hata T, Ikenaga M, Takemasa I, Mizushima T, Kato T, et
al: Randomized phase II study of S-1 dosing schedule for resected
colorectal cancer. BMC Cancer. 15:4522015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chibaudel B, Maindrault-Goebel F, Lledo G,
Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch
M, et al: Can chemotherapy be discontinued in unresectable
metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin
Oncol. 27:5727–5733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goey KKH, Elias SG, van Tinteren H, Laclé
MM, Willems SM, Offerhaus GJA, de Leng WWJ, Strengman E, Ten Tije
AJ, Creemers GM, et al: Maintenance treatment with capecitabine and
bevacizumab versus observation in metastatic colorectal cancer:
Updated results and molecular subgroup analyses of the phase 3
CAIRO3 study. Ann Oncol. 28:2128–2134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dy GK, Krook JE, Green EM, Sargent DJ,
Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK,
Findlay BP, et al: Intergroup N9741: Impact of complete response to
chemotherapy on overall survival in advanced colorectal cancer:
Results from Intergroup N9741. J Clin Oncol. 25:3469–3474. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH,
Yen CC, Chen WS, Jiang JK, Yang SH, Wang HS, et al: Tumor marker
CEA in monitoring of response to tegafur-uracil and folinic acid in
patients with metastatic colorectal cancer. Hepatogastroenterology.
49:388–392. 2002.PubMed/NCBI
|
|
17
|
Satoh Y, Ichikawa T, Motosugi U, Kimura K,
Sou H, Sano K and Araki T: Diagnosis of peritoneal dissemination:
Comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and
contrast-enhanced MDCT. AJR Am J Roentgenol. 196:447–453. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patel CM, Sahdev A and Reznek RHCT: CT,
MRI and PET imaging in peritoneal malignancy. Cancer Imaging.
11:123–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kishiki T, Lapin B, Matsuoka H, Watanabe
T, Takayasu K, Kojima K, Sugihara K and Masaki T: Optimal
surveillance protocols after curative resection in patients with
stage IV colorectal cancer: A multicenter retrospective study. Dis
Colon Rectum. 61:51–57. 2018.PubMed/NCBI
|
